Advertisement

Metabolomics

, Volume 11, Issue 4, pp 998–1012 | Cite as

Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare)

  • David B. Liesenfeld
  • Nina Habermann
  • Reka Toth
  • Robert W. Owen
  • Eva Frei
  • Jürgen Böhm
  • Petra Schrotz-King
  • Karel D. Klika
  • Cornelia M. UlrichEmail author
Original Article

Abstract

Metabolomics is a valuable tool for biomarker screening of colorectal cancer (CRC). In this study, we profiled the urinary metabolomes of patients enrolled in a prospective patient cohort (ColoCare). We aimed to determine changes in the metabolome of the longer clinical follow-up and ascertain candidate markers with possibly prognostic significance. In total, 199 urine samples from CRC patients prior to surgery (n = 97) or 1–8 days post-surgery (n = 12), and then after 6 (n = 52) and 12 months (n = 38) were analyzed using both GC–MS and 1H-NMR. Both datasets were analyzed separately with built in uni- and multivariate analyses of Metaboanalyst 2.0. Furthermore, adjusted linear mixed effects regression models were constructed. Many concentrations of the metabolites derived from the gut microbiome were affected by CRC surgery, presumably indicating a tumor-induced shift in bacterial species. Associations of the microbial metabolites with disease stage indicate an important role of the gut microbiome in CRC. We were able to differentiate the metabolite profiles of pre-surgery CRC patients from those at any post-surgery timepoint using a multivariate model containing 20 marker metabolites (AUCROC = 0.89; 95 % CI 0.84–0.95). This is one of the first metabolomic studies to follow CRC patients in a prospective setting with repeated urine sampling over time. We were able to confirm markers initially identified in case–control studies and metabolites which may represent prognostic biomarker candidates of CRC.

Keywords

Colorectal cancer Biomarkers Cohort Gas chromatography–mass spectrometry (GC–MS) Nuclear magnetic resonance (NMR) Metabolomics 

Notes

Acknowledgments

The ColoCare study has been funded by the German Consortium for Translational Cancer Research (DKTK), Matthias Lackas Foundation and the Helmholtz International Graduate School for Cancer Research, Heidelberg. We thank our collaborators, in particular Prof. Hermann Brenner, Prof. Jenny Chang-Claude and Dr. Michael Hoffmeister. We also thank all the study staff who through their energy and effort have made this study possible, particularly Dr. Clare Abbenhardt, Dr. Stephanie Zschäbitz, Thorsten Kölsch, Judith Kammer, Stephanie Tosic, Verena Widmer, Manja Ghajar Rahimi, Biljana Gigic, Werner Diehl, Rifraz Farook and many others. Last, we are truly grateful for the time and cooperation of our study participants.

Conflict of interest

The authors declare that there are no conflicts of interest.

Compliance with ethical requirements

The ColoCare study has been approved by the ethics committee of the medical faculty at the University of Heidelberg and study participants provided their written informed consent.

Supplementary material

11306_2014_758_MOESM1_ESM.docx (2.3 mb)
Supplementary material 1 (DOCX 2340 kb)
11306_2014_758_MOESM2_ESM.xlsx (22 kb)
Supplementary material 2 (XLSX 22 kb)

References

  1. Aa, J., et al. (2012). Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment. Metabolomics, 8, 164–173.CrossRefGoogle Scholar
  2. ACS. (2013). Cancer facts & figures 2013. Atlanta: ACS.Google Scholar
  3. Barupal, D. K., et al. (2012). MetaMapp: Mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics, 13, 99.PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bates, D., Maechler, M., Bolker, B., & Walker, S. (2013). lme4: Linear mixed-effects models using Eigen and S4. http://CRAN.R-project.org/package=lme4. Accessed 15 Oct 2014.
  5. Beck, S. A., & Tisdale, M. J. (1989). Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Research, 49, 3800–3804.PubMedGoogle Scholar
  6. Bellomi, M., et al. (2005). Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. European Radiology, 15, 2469–2474.PubMedCrossRefGoogle Scholar
  7. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological), 57, 289–300.Google Scholar
  8. Biondi, A., et al. (2013). Laparoscopic vs. open approach for colorectal cancer: Evolution over time of minimal invasive surgery. BMC surgery, 13, 1471–2482.CrossRefGoogle Scholar
  9. Bone, E., Tamm, A., & Hill, M. (1976). The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. American Journal of Clinical Nutrition, 29, 1448–1454.PubMedGoogle Scholar
  10. Boutwell, R. K., & Bosch, D. K. (1959). The tumor-promoting action of phenol and related compounds for mouse skin. Cancer Research, 19, 413–424.PubMedGoogle Scholar
  11. Carman, R. J., Van Tassell, R. L., Kingston, D. G., Bashir, M., & Wilkins, T. D. (1988). Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutation Research, 206, 335–342.PubMedCrossRefGoogle Scholar
  12. Chan, E. C., et al. (2009). Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). Journal of Proteome Research, 8, 352–361.PubMedCrossRefGoogle Scholar
  13. Cheng, Y., et al. (2012). Distinct urinary metabolic profile of human colorectal cancer. Journal of Proteome Research, 11, 1354–1363.PubMedCrossRefGoogle Scholar
  14. Chowdhury, R., Yeoh, K. K., Tian, Y. M., Hillringhaus, L., Bagg, E. A., Rose, N. R.,et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 12(5), 463–469. doi: 10.1038/embor.2011.43
  15. Denkert, C., et al. (2008). Metabolite profiling of human colon carcinoma: Deregulation of TCA cycle and amino acid turnover. Molecular Cancer, 7, 72.PubMedCentralPubMedCrossRefGoogle Scholar
  16. Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 25, 9–34.PubMedCrossRefGoogle Scholar
  17. Dunn, W. B., et al. (2011). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols, 6, 1060–1083.PubMedCrossRefGoogle Scholar
  18. Farshidfar, F., et al. (2012). Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Medicine, 4, 2–13.CrossRefGoogle Scholar
  19. Ferlay, J., et al. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer, 49, 1374–1403.PubMedCrossRefGoogle Scholar
  20. Heavey, P. M., & Rowland, I. R. (2004). Microbial–gut interactions in health and disease. Gastrointestinal cancer. Best Practice & Research Clinical Gastroenterology, 18, 323–336.CrossRefGoogle Scholar
  21. Højsgaard, U. H. S. (2013). pbkrtest: Parametric bootstrap and Kenward Roger based methods for mixed model comparison. http://CRAN.R-project.org/package=pbkrtest. Accessed 15 Oct 2014.
  22. Kanani, H., Chrysanthopoulos, P. K., & Klapa, M. I. (2008). Standardizing GC–MS metabolomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 871, 191–201.PubMedCrossRefGoogle Scholar
  23. Kern, K. A., & Norton, J. A. (1988). Cancer cachexia. JPEN Journal of Parenteral and Enteral Nutrition, 12, 286–298.PubMedCrossRefGoogle Scholar
  24. Kind, T., Tolstikov, V., Fiehn, O., & Weiss, R. H. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancer. Analytical Biochemistry, 363, 185–195.PubMedCrossRefGoogle Scholar
  25. Kondo, Y., et al. (2011). Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomarkers in Medicine, 5, 451–460.PubMedCrossRefGoogle Scholar
  26. Leichtle, A. B., et al. (2012). Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics, 8, 643–653.PubMedCentralPubMedCrossRefGoogle Scholar
  27. Liesenfeld, D. B., Habermann, N., Owen, R. W., Scalbert, A., & Ulrich, C. M. (2013). Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prevention, 22, 2182–2201.CrossRefGoogle Scholar
  28. Losman, J. A., & Kaelin, W. G., Jr. (2013). What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development, 27, 836–852.CrossRefGoogle Scholar
  29. Ma, Y. L., et al. (2009). Ultra-high performance liquid chromatography–mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Digestive Diseases and Sciences, 54, 2655–2662.PubMedCrossRefGoogle Scholar
  30. Maeda, J., et al. (2010). Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer, 10, 690–698.PubMedCentralPubMedCrossRefGoogle Scholar
  31. Mal, M., Koh, P. K., Cheah, P. Y., & Chan, E. C. Y. (2009). Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Communications in Mass Spectrometry, 23, 487–494.PubMedCrossRefGoogle Scholar
  32. Mal, M., Koh, P. K., Cheah, P. Y., & Chan, E. C. Y. (2012). Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 403, 483–493.PubMedCrossRefGoogle Scholar
  33. Marchesi, J. R., et al. (2011). Towards the Human Colorectal Cancer Microbiome. PLoS One, 6, e20447.PubMedCentralPubMedCrossRefGoogle Scholar
  34. Miyagi, Y., et al. (2011). Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One, 6, e24143.PubMedCentralPubMedCrossRefGoogle Scholar
  35. Moffett, J. R., & Namboodiri, M. A. (2003). Tryptophan and the immune response. Immunology and Cell Biology, 81, 247–265.PubMedCrossRefGoogle Scholar
  36. Nambiar, P. R., Gupta, R. R., & Misra, V. (2010). An “Omics” based survey of human colon cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 693, 3–18.CrossRefGoogle Scholar
  37. Nishiumi, S., et al. (2012). A novel serum metabolomics-based diagnostic approach for colorectal cancer. Plos One, 7, e40459.PubMedCentralPubMedCrossRefGoogle Scholar
  38. Normanno, N., et al. (2013). Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. Journal of Cellular Biochemistry, 114, 514–524.PubMedCrossRefGoogle Scholar
  39. Opitz, C. A., et al. (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478, 197–203.PubMedCrossRefGoogle Scholar
  40. Owen, R. W., Spiegelhalder, B., & Bartsch, H. (2000). Generation of reactive oxygen species by the faecal matrix. Gut, 46, 225–232.PubMedCentralPubMedCrossRefGoogle Scholar
  41. Paxton, R., Scislowski, P. W., Davis, E. J., & Harris, R. A. (1986). Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism. Biochemical Journal, 234, 295–303.PubMedCentralPubMedGoogle Scholar
  42. Perroud, B., et al. (2006). Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer, 5, 1–17.CrossRefGoogle Scholar
  43. Pluskal, T., Castillo, S., Villar-Briones, A., & Oresic, M. (2010). MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics, 11, 395–406.PubMedCentralPubMedCrossRefGoogle Scholar
  44. Pollard, P. J., et al. (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics, 14, 2231–2239.PubMedCrossRefGoogle Scholar
  45. Qiu, Y. P., et al. (2009). Serum metabolite profiling of human colorectal cancer using GC–TOFMS and UPLC–QTOFMS. Journal of Proteome Research, 8, 4844–4850.PubMedCrossRefGoogle Scholar
  46. Qiu, Y. P., et al. (2010). Urinary metabonomic study on colorectal cancer. Journal of Proteome Research, 9, 1627–1634.PubMedCrossRefGoogle Scholar
  47. Ritchie, S. A., et al. (2010). Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Medicine, 8, 1–20.CrossRefGoogle Scholar
  48. Steele, R. D. (1982). Transaminative metabolism of alpha-amino-n-butyrate in rats. Metabolism, 31, 318–325.PubMedCrossRefGoogle Scholar
  49. Sumner, L., et al. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics, 3, 211–221.PubMedCentralPubMedCrossRefGoogle Scholar
  50. Thysell, E., et al. (2010). Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One, 5, e14175.PubMedCentralPubMedCrossRefGoogle Scholar
  51. van den Berg, R., Hoefsloot, H., Westerhuis, J., Smilde, A., & van der Werf, M. (2006). Centering, scaling, and transformations: Improving the biological information content of metabolomics data. BMC Genomics, 7, 142.PubMedCentralPubMedCrossRefGoogle Scholar
  52. Wang, W. Z., et al. (2010). Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography–mass spectrometry. Molecular Biosystems, 6, 1947–1955.PubMedCrossRefGoogle Scholar
  53. Warrack, B. M., et al. (2009). Normalization strategies for metabonomic analysis of urine samples. Journal of Chromatography B, 877, 547–552.CrossRefGoogle Scholar
  54. Wu, H., et al. (2009). Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Analytica Chimica Acta, 648, 98–104.PubMedCrossRefGoogle Scholar
  55. Xia, J., Broadhurst, D., Wilson, M., & Wishart, D. S. (2013). Translational biomarker discovery in clinical metabolomics: An introductory tutorial. Metabolomics, 9, 280–299.PubMedCentralPubMedCrossRefGoogle Scholar
  56. Xia, J., Mandal, R., Sinelnikov, I. V., Broadhurst, D., & Wishart, D. S. (2012). MetaboAnalyst 2.0—A comprehensive server for metabolomic data analysis. Nucleic Acids Research, 40, 2.CrossRefGoogle Scholar
  57. Xiao, C., Hao, F., Qin, X., Wang, Y., & Tang, H. (2009). An optimized buffer system for NMR-based urinary metabonomics with effective pH control, chemical shift consistency and dilution minimization. Analyst, 134, 916–925.PubMedCrossRefGoogle Scholar
  58. Zhang, X., et al. (2012). Metabolite profiling of plasma and urine from rats with TNBS-induced acute colitis using UPLC–ESI–QTOF–MS-based metabonomics—A pilot study. FEBS Journal, 279, 2322–2338.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • David B. Liesenfeld
    • 1
    • 4
  • Nina Habermann
    • 1
    • 4
  • Reka Toth
    • 1
    • 4
  • Robert W. Owen
    • 1
    • 4
  • Eva Frei
    • 1
    • 4
  • Jürgen Böhm
    • 1
    • 4
  • Petra Schrotz-King
    • 1
    • 4
  • Karel D. Klika
    • 2
  • Cornelia M. Ulrich
    • 1
    • 3
    • 4
    • 5
    Email author
  1. 1.Division of Preventive Oncology, National Center for Tumor Diseases (NCT)German Cancer Research Center (DKFZ)HeidelbergGermany
  2. 2.Genomics and Proteomics Core Facility, Molecular Structure AnalysisGerman Cancer Research Center (DKFZ)HeidelbergGermany
  3. 3.Fred Hutchinson Cancer Research Center (FHCRC)SeattleUSA
  4. 4.German Consortium for Translational Cancer Research (DKTK)HeidelbergGermany
  5. 5.Population SciencesHuntsman Cancer InstituteSalt Lake CityUSA

Personalised recommendations